-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoThe Analytical Blueprint for Cell & Gene Therapy Success
This eBook brings together expert perspectives on several of the most pressing analytical topics facing today’s cell and gene therapy developers. The post The Analytical Blueprint...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoThe hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoSTAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoEight-letter DNA alphabet is accurately transcribed by a natural enzyme
All known life on Earth uses the same genetic alphabet, consisting of four letters. Now, researchers at the University of California San Diego have demonstrated that...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoWhat CAR T’s new safety concern could mean for immune reset competition
BIOCENTURY | PRODUCT DEVELOPMENTWHAT CAR T’S NEW SAFETY CONCERN COULD MEAN FOR IMMUNE RESET COMPETITIONNovartis discloses three autoimmune disease patient deaths after CAR T cell therapy
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoSTAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoThe hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoA pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR
Nature Biotechnology, Published online: 01 September 2026; doi:10.1038/s41587-026-03291-1A quantification artifact confounds CRISPR-mediated RNA knockdown.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoNew gene activation tool may do what CRISPR cannot: Work inside the body
The ability to precisely adjust the expression of genes inside the human body—ramping up protective ones and tamping down harmful ones—holds enormous potential for treating and...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 months agoSTAT+: Can a pregnancy hormone steer a cardiovascular treatment?
Caution and survival in radiopharmaceuticals, mRNA skepticism, and more biotech news from The Readout
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
